We intend to quantify the causal role of endothelial to mesenchymal transition (EndMT) in human cardiovascular disease by studying the mechanisms and functional contributions of this process to cardiovascular development and adult cardiovascular disease. Our ultimate goal is to develop therapies that correct EndMT as a new treatment for patients with cardiovascular diseases.
We recently published a state-of-the-art review in the Journal of the American College of Cardiology:
Endothelial to Mesenchymal Transition in Cardiovascular Disease. J C Kovacic, S Dimmeler, R P Harvey, T Finkel, E Aikawa, G Krenning, A H. Baker.
JACC Jan 2019, 73 (2) 190-209; https://doi.org/10.1016/j.jacc.2018.09.089